Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.
BACKGROUND
Beta2-microglobulin (beta2m) is a major component in dialysis-related amyloidosis, a disabling disease affecting long-term dialysis patients.


METHODS
Beta2m and other components were analyzed in saliva and serum from 53 individuals in 4 subgroups: healthy normal controls, diabetes mellitus (DM), chronic kidney disease (CKD) and hemodialysis (HD) patients.


RESULTS
Median salivary and mean serum beta2m concentrations were 78% higher in both saliva (p = 0.048) and serum (p = 0.047) in DM patients; 118% (p = 0.016) and 907% (p = 0.007) higher, respectively, in CKD patients, and 328% (p = 0.0001) and 2,710% (p = 0.001) higher, respectively, in HD patients, compared with healthy controls. The correlation analysis between salivary and serum beta2m concentrations showed a low correlation rate in HD patients (r = -0.18), but was rather high in CKD patients (r = 0.50).


CONCLUSIONS
Salivary analysis of beta2m is a reliable method for evaluating serum beta2m levels in CKD patients, and may help predict the potential for development of CKD-induced amyloidosis.
Michelis
Regina
R
Eliachar Research Laboratory, Western Galilee Hospital, Nahariya, Israel.
Sela
Shifra
S
Ben-Zvi
Ilan
I
Nagler
Rafael M
RM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000175:diagnosis; D016022:Case-Control Studies; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012463:Saliva / Q000737:chemistry*; D001613:beta 2-Microglobulin / Q000032:analysis* / Q000097:blood
D001613:beta 2-Microglobulin